期刊文献+

8-溴-6-甲基-2-(1-吡咯烷基羰基)咪唑并[1,2-a]吡啶的合成及晶体结构

Synthesis and Crystal Structure of(8-Bromo-6-methylimidazo[1,2-a]pyridin-2-yl)(pyrrolidin-1-yl)methanone
下载PDF
导出
摘要 以2-氨基-5-甲基吡啶为原料,经溴代、环合、水解及酰胺化反应合成了8-溴-6-甲基-2-(1-吡咯烷基羰基)咪唑并[1,2-a]吡啶,总收率32.82%,其结构经1H-NMR和MS确证,并用X-单晶衍射法测定了其晶体结构。结果表明:待测物块状晶体a(CCDC:2039002)属三斜晶系,空间群P-1,晶胞参数a=6.3447(2)A,b=8.6251(3)A,c=11.4553(4)A,β=88.2300(10)°,V=624.47(4)A3,Z=2,Rgt(F)=0.0261,ωRref(F2)=0.0637,F(000)=314,μ=3.283 mm^(-1)。该路线反应条件温和、后处理简便且收率较高,适合工业化生产。 The title compound is an important pharmaceutical intermediate,which is fist obtained through bromination,cyclization and hydrolysis and amidation reaction from 5-methylpyridin-2-amine.The total yield was 32.82%.The structure was confirmed by 1H-NMR,MS and the molecularstructure was determined by X-single crystal diffraction.The results show that the title compound a(CCDC:2039002)belongs to triclinic system,space groupP-1,unit cell parametersa=6.3447(2)A,b=8.6251(3)A,c=11.4553(4)A,β=88.2300(10)°,V=624.47(4)A3,Z=2,Rgt(F)=0.0261(2256),ωRref(F2)=0.0637(2512),F(000)=314,μ=3.23 mm^(-1).This route has the advantages of mild reaction conditions,simple post-treatment and high yield,which is a synthetic route suitable for industrial production.
作者 毛顺艺 高婷 骆荣双 刘春江 柴慧芳 赵春深 MAO Shun-yi;GAO Ting;LUO Rong-shuang;LIU Chun-jiang;CHAI Hui-fang;ZHAO Chun-shen(School of Pharmaceutical Sciences,Guizhou University,Guiyang 550025,China;Guizhou Engineering Laboratory for Synthetic Drugs,Guiyang 550025,China;School of Pharmaceutical Sciences,Guizhou University of Traditional Chinese Medicine,Guiyang 550025,China)
出处 《广州化学》 CAS 2021年第3期47-53,共7页 Guangzhou Chemistry
基金 贵州中医药大学2018年度学术新苗培养及创新探索专项项目培育项目计划(黔科合平台人才[2018]5766号-14)。
关键词 2-氨基-5-甲基吡啶 8-溴-6-甲基-2-(1-吡咯烷基羰基)咪唑并[1 2-a]吡啶 合成 晶体结构 5-methylpyridin-2-amine (8-bromo-6-methylimidazo[1,2-a]pyridin-2-yl)(pyrrolidin-1-yl)methanone synthesis crystal structure
  • 相关文献

参考文献2

二级参考文献45

  • 1FELDMAN AM, BRISTOW MR, PARMLEY WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group[J]. N Engl J Med, 1993, 329 (3): 149-155.
  • 2TAKAOKA H, TAKEUCHI M, ODAKE M, et al. Comparison of the effects on arterial-ventricular coupling between phospho- diesterase inhibitor and dobutamine in the diseases human heart [J]. J Am Coll Cardiol, 1993, 22(2) : 598-606.
  • 3MIZUSHIGE K, UEDA T, YUKIIRI K, et al. Olprinone: a phosphodiesterase Ⅲ inhibitor with positive inotropic and vasodi- lator effects[J]. Cardiovase Drug Rev, 2002, 20(3): 163-174.
  • 4UNOSHIMA M, IWASAKA H, HATTORI S, et al. Effects of loprinone hydrochloride on hemodynamics and respiratory oxygenation in patients after cardiac surgery[J]. Masui, 1997, 46 (8) : 1053-1058.
  • 5YU Y, MIZUSHIGE K, UEDA T, et al. Effect of olprinone, phosphodiesterase Ⅲ inhibitor, on cerebral blood flow assessed with technetium-99m-ECD SPECT[J]. J Cardiovasc Pharmacol, 2000, 35(3) : 422-426.
  • 6SATO K, YOSHIMOTO A. Effects of olprinone on systemic and cerebral circulation in patients with subarachnoid hemorrhage[J]. J Neurosurg Anesthesiol, 2000, 12(2) : 81-83.
  • 7MINONISHI T, OGAWA K, TOKINAGA Y, et al. Differential vasodilation response to olprinone in rabbit renal and common carotid arteries[J]. J Anesth, 2010, 24(1): 61-66.
  • 8SUGIOKA M, ITO M, MASUOKA H, et al. Identification and characterization of isoenzymes of cyclic nueleotide phospho- diesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes[J]. Naunyn Schmiedebergs Arch Pharmaeol, 1994, 350(3): 284-293.
  • 9PACKER M, CARVER JR, RODEHEFFER R J, et al. Effect of oral milrinone on mortality in severe chronic heart failure [J]. N Engl J Med, 1991, 325(21): 1468-1475.
  • 10FUJII Y, TOYOOKA H. Different effects of olprinone on contrac- tility in nonfatigued and fatigued diaphragm in dogs [J]. Can J Anaesth, 2000, 47(12): 1243-1248.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部